Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational study.

Date publication

août 2025

Journal

Multiple sclerosis and related disorders

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Didierjean J, Kremer L, Lanotte L, Courtois S, Carré G, Collongues N, De Seze J, Bigaut K

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41014778

Résumé

The evolution of the therapeutic arsenal, diagnostic criteria and recommendations concerning treatment in multiple sclerosis (MS) have led to a change in the practices of neurologists in this disease. Our study focuses on the evolution of the prescriptions of a disease-modifying treatment (DMT) in relapsing-remitting (RR) MS by neurologists with a private practice, hospital, or MS center activity, between 2007 (introduction of natalizumab) and 2022 (current practice).

Mots clés

Disease-modifying treatment, Early intensive, Evolution, Flipping the pyramid, Multiple sclerosis, Observational study, Strategy

Référence

Mult Scler Relat Disord. 2025 08 17;104:106690